Mesoblast

Yahoo Finance • 11 days ago

Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-r... Full story

Yahoo Finance • 22 days ago

Mesoblast enters option to issue $50M convertible notes

* Mesoblast (OTCPK:MEOBF [https://seekingalpha.com/symbol/MEOBF]) entered into convertible note [https://seekingalpha.com/pr/20220508-mesoblast-enters-into-option-to-issue-us-50-million-convertible-notes] subscription agreements with Sur... Full story

Yahoo Finance • 22 days ago

Mesoblast Secures Up To US$50 Mln In Convertible Note Agreements With Key Investors

(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced that it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck, to issue up to US$50... Full story

Yahoo Finance • 22 days ago

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements... Full story

Yahoo Finance • 28 days ago

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period end... Full story

Yahoo Finance • 2 months ago

Mesoblast Limited (MESO) Launches First Cell Therapy for Children

We recently compiled a list of 10 Best Mid Cap Stocks to Buy According to Billionaires. Mesoblast Limited stands tenth on our list and has launched the first cell therapy for children. Mesoblast Limited (NASDAQ:MESO) is among the best mid... Full story

Yahoo Finance • 2 months ago

Jefferies downgrades Mesoblast stock to Hold despite price target increase

Investing.com - Jefferies downgraded Mesoblast Limited (NASDAQ:MESO) (ASX:MSB) from Buy to Hold while raising its price target to AUD2.60 from AUD2.50. Despite the downgrade, InvestingPro data shows MESO has delivered an impressive 73.8%... Full story

Yahoo Finance • 3 months ago

Mesoblast, FDA agree on marketing application for cell therapy

[FDA headquarters in Washington DC.] JHVEPhoto Mesoblast (NASDAQ:MESO [https://seekingalpha.com/symbol/MESO]) added ~13% in the morning hours on Tuesday after the Australian biotech said that the FDA agreed with the company regarding key... Full story

Yahoo Finance • 3 months ago

Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L) for treating steroid-refractory acute... Full story

Yahoo Finance • 3 months ago

Mesoblast Moves Closer To FDA Approvals For Heart And Immune Disorder Treatments

(RTTNews) - Mesoblast (MESO, MSB.AX) has shared an update about its progress with the U.S. Food and Drug Administration. The company is working toward faster approval for its heart failure treatment, Revascor, aimed at patients with reduce... Full story

Yahoo Finance • 7 months ago

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies... Full story

Yahoo Finance • last year

Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?

We recently published a list of 10 Best Australian Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Mesoblast (NASDAQ:MESO) stands against the other Australian stocks. A Look at Australia’s Eco... Full story

Yahoo Finance • 2 years ago

10 Best Australian Stocks To Buy

In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To B... Full story

Yahoo Finance • 2 years ago

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mesoblast Limited - MESO

NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO). Such investors are advised to contact Robert S. Willoughby at n... Full story

Yahoo Finance • 2 years ago

Appendix 4C Quarterly Activity Report

Mesoblast Limited Mesoblast Financial and Operational Highlights for Quarter Ended March 31, 2023 NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for i... Full story

Yahoo Finance • 3 years ago

Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022

Mesoblast Limited NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results... Full story

Yahoo Finance • 3 years ago

Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recently published studies of ch... Full story

Yahoo Finance • 3 years ago

Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022

NEW YORK, Oct. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the fourth quarter ended September 30,... Full story

Yahoo Finance • 3 years ago

Mesoblast Key Opinion Leader Event Series for Investors & Analysts

Mesoblast Limited Chronic Low Back Pain due to Degenerative Disc Disease NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will... Full story